Status:
TERMINATED
Fecal Microbiota Transplantation as a Treatment for Ulcerative Colitis
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Ulcerative Colitis
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Ulcerative colitis (UC) is characterized by a disrupted homeostasis of the commensal bacterial population (dysbiosis). A promising therapy for restoration of the altered balance of the enteric microbi...
Eligibility Criteria
Inclusion
- Over 3 month diagnosis of ulcerative colitis
- Active Colitis disease with endoscopic score \>0
- Ability to sign an informed consent
Exclusion
- Acute neutrophilia (under 500 neutrophils)
- Clostridium difficile infection
- Exposure to antibiotics 2 weeks prior to enrollment.
- Severe immune deficiency
- Hospitalization
- Proctitis involving less than 10cm of the rectum
- Malignancy with the past 5 years (excluding BCC)
- An unstable dose of steroids or 5ASA (5- aminosalicylic acid) with the past 2 weeks or of immunomodulators or biologic therapy within the past 12 weeks
Key Trial Info
Start Date :
July 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04434872
Start Date
July 1 2015
End Date
July 1 2016
Last Update
June 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gastroentherology
Tel Aviv, Israel, 64239